Efficacy and Optimal Dose of Coenzyme Q10 Supplementation on Inflammation‐Related Biomarkers: A GRADE‐Assessed Systematic Review and Updated Meta‐Analysis of Randomized Controlled Trials

Abstract

ScopeCoenzyme Q10 (CoQ10) has become a popular nutritional supplement due to its wide range of beneficial biological effects. Previous meta‐analyses show that the attenuation of CoQ10 on inflammatory biomarkers remains controversial. This meta‐analysis aims to assess the efficacy and optimal dose of CoQ10 supplementation on inflammatory indicators in the general population.Methods and resultsDatabases are searched up to December 2022 resulting in 6713 articles, of which 31 are retrieved for full‐text assessment and included 1517 subjects. Double‐blind randomized controlled trials (RCTs) of CoQ10 supplementation are eligible if they contain C reactive protein (CRP), interleukin‐6 (IL‐6), and tumor necrosis factor‐α (TNF‐α). CoQ10 supplementation can significantly reduce the levels of circulating CRP (SMD: −0.40, 95% CI: [−0.67 to −0.13], p = 0.003), IL‐6 (SMD: −0.67, 95% CI: [−1.01 to −0.33], p < 0.001), and TNF‐α (SMD: −1.06, 95% CI: [−1.59 to −0.52], p < 0.001) and increase the concentration of circulating CoQ10.ConclusionThis meta‐analysis provides evidence for CoQ10 supplementation to reduce the level of inflammatory mediators in the general population and proposes that daily supplementation of 300–400 mg CoQ10 show superior inhibition of inflammatory factors.